This product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 769-P human renal epithelial carcinoma line, targeting the EIF2AK3 gene that encodes the ER stress sensor kinase PERK. PERK is a central regulator of the unfolded protein response (UPR), activated by accumulation of misfolded proteins in the ER. The polyclonal nature of this population provides a diverse genetic background, mitigating clonal selection artifacts and reflecting tumor heterogeneity. CRISPR/Cas9-mediated disruption efficiently ablates PERK function, enabling loss-of-function studies of downstream pathways.
The 769-P host cells originate from a human clear cell renal cell carcinoma (ccRCC), a common kidney cancer subtype characterized by VHL loss and pseudo-hypoxic signaling. These renal epithelial cells are extensively used to model ccRCC biology, drug sensitivity, and metabolic adaptations. Their tumor-derived context makes them particularly relevant for investigating how ER stress pathways, including PERK signaling, contribute to kidney cancer cell survival, proliferation, and therapeutic resistance.
EIF2AK3/PERK resides in the ER membrane and is normally kept inactive by association with the chaperone BiP/GRP78. Under stress conditions such as hypoxia, oxidative stress, or glucose deprivation, BiP dissociates, allowing PERK dimerization and autophosphorylation. Active PERK then phosphorylates eIF2??, globally attenuating translation while selectively enhancing translation of ATF4. ATF4 transcriptionally upregulates genes including CHOP (DDIT3) and GADD34, and PERK also activates NRF2 to promote an antioxidant response. PERK interacts with TRAF2 and IRE1, integrating the UPR with inflammatory and survival signals. The balance between adaptive and apoptotic outcomes is determined by stress severity, with CHOP driving cell death under prolonged ER stress.
In the 769-P ccRCC model, PERK signaling is often mobilized to cope with chronic ER stress induced by oncogenic metabolism and the tumor microenvironment. Abrogating EIF2AK3 in this polyclonal background allows systematic dissection of how PERK-dependent cytoprotection influences sensitivity to chemotherapeutics, apoptosis thresholds, and invasive potential. This knockout model is therefore valuable for examining the functional importance of the PERK?CeIF2???CATF4 axis in renal carcinoma, and for assessing therapeutic strategies that target the integrated stress response.
Typical applications include Western blotting for PERK and phospho-eIF2??, RT-qPCR for ATF4 and CHOP, and sensitivity assays using tunicamycin or thapsigargin. This model also enables ATF4 luciferase reporter assays, apoptosis quantification, and migration/invasion studies. It is ideally suited for PERK inhibitor validation and investigation of ER stress contributions to kidney cancer progression. For further information or technical guidance, please contact Ascent Research.
